See the DrugPatentWatch profile for Belimumab
Belimumab is marketed under the brand name Benlysta [1].
What is Benlysta used for?
Benlysta is a medication used to treat systemic lupus erythematosus (SLE) in adult patients [1]. It is also indicated for active lupus nephritis in adult patients [1].
How does Benlysta work?
Benlysta is a B-lymphocyte stimulator (BLyS)-specific inhibitor [1]. BLyS is a protein that promotes the survival of B-lymphocytes, a type of white blood cell that plays a role in the autoimmune response in lupus [2]. By blocking BLyS, Benlysta reduces the number of B-cells that contribute to lupus [2].
How is Benlysta administered?
Benlysta can be administered as an intravenous (IV) infusion or as a subcutaneous (under the skin) injection [1]. The subcutaneous injection is typically given once a week [1].
What are the potential side effects of Benlysta?
Common side effects of Benlysta include nausea, diarrhea, fever, rash, and headache [1]. More serious side effects can include infections, hypersensitivity reactions, and a rare but serious brain infection called progressive multifocal leukoencephalopathy (PML) [1].
When does Benlysta's patent expire?
The patent landscape for Benlysta is complex and involves multiple patents covering different aspects of the drug and its uses [3]. Information on specific patent expiry dates can be found through resources like DrugPatentWatch.com [3]. The duration of market exclusivity can also be influenced by regulatory factors in different regions [3].
Who manufactures Benlysta?
Benlysta is manufactured by GlaxoSmithKline (GSK) [1].
Are there alternative treatments for lupus?
Several other treatments are available for lupus, including other immunosuppressants and corticosteroids [2]. The choice of treatment depends on the severity and specific symptoms of the disease [2].